
## Patrizia Carrieri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5647412/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. International Journal of Obesity, 2012, 36, 817-825.	1.6	567
2	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer Clinical Cancer Research, 2006, 12, 1157-1167.	3.2	495
3	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
4	Risks Factors and Prevention of Q Fever Endocarditis. Clinical Infectious Diseases, 2001, 33, 312-316.	2.9	264
5	The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	6.3	257
6	Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. Aids, 2001, 15, 2441-2444.	1.0	247
7	Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. Aids, 2000, 14, 151-155.	1.0	193
8	The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 232-239.	0.9	163
9	Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. European Journal of Cancer, 2007, 43, 2117-2123.	1.3	127
10	Buprenorphine Use: The International Experience. Clinical Infectious Diseases, 2006, 43, S197-S215.	2.9	125
11	Nonadherence Among HIV-Infected Injecting Drug Users: The Impact of Social Instability. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S149-S153.	0.9	120
12	Health-Related Quality of Life After 1 Year of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 38-47.	0.9	113
13	Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Annals of Oncology, 2012, 23, 882-890.	0.6	107
14	Cancer risk among men with, or at risk of, HIV infection in southern Europe. Aids, 2000, 14, 553-559.	1.0	105
15	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Journal of Hepatology, 2018, 68, 402-411.	1.8	105
16	HIV infection among persons who inject drugs. Aids, 2016, 30, 815-826.	1.0	100
17	Factors Associated With Nonadherence to Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 477-485.	0.9	96
18	Failure to maintain adherence to haart in a cohort of French HIV-positive injecting drug users. International Journal of Behavioral Medicine, 2003, 10, 1-14.	0.8	93

#	Article	IF	CITATIONS
19	A Case-Control Study on Risk Factors for Peyronie's Disease. Journal of Clinical Epidemiology, 1998, 51, 511-515.	2.4	91
20	Risk of invasive cervical cancer among women with, or at risk for, HIV infection. , 1999, 82, 334-337.		90
21	Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. Journal of Epidemiology and Community Health, 1999, 53, 4-8.	2.0	87
22	Health-related quality of life and patient–provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2004, 16, 649-661.	0.6	87
23	Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infectious Diseases, The, 2011, 11, 825-833.	4.6	83
24	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study. Lancet, The, 2010, 376, 340-345.	6.3	82
25	Reduced incidence of kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. International Journal of Cancer, 2003, 103, 142-144.	2.3	80
26	The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13) Tj ETQq0 0 0 rgI	3T /Oyerlo 1.3	ck 10 Tf 50 46
27	Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. The Lancet Gastroenterology and Hepatology. 2017. 2. 177-188.	3.7	79
28	Patient-reported outcomes to enhance person-centred HIV care. Lancet HIV,the, 2020, 7, e59-e68.	2.1	79
29	B-cell non-Hodgkin lymphoma linked to Coxiella burnetii. Blood, 2016, 127, 113-121.	0.6	78
30	Self-Reported Fatigue and Depressive Symptoms as Main Indicators of the Quality of Life (QOL) of Patients Living with HIV and Hepatitis C: Implications for Clinical Management and Future Research. HIV Clinical Trials, 2007, 8, 320-327.	2.0	68
31	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nature Communications, 2021, 12, 4450.	5.8	67
32	The negative impact of <scp>HBV</scp> / <scp>HCV</scp> coinfection on cirrhosis and its consequences. Alimentary Pharmacology and Therapeutics, 2017, 46, 1054-1060.	1.9	66
33	Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. International Journal of Cardiology, 2013, 168, 568-569.	0.8	65
34	20 Years into the Gambia Hepatitis Intervention Study: Assessment of Initial Hypotheses and Prospects for Evaluation of Protective Effectiveness Against Liver Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3216-3223.	1.1	63
35	Risk factors for nosocomial sepsis in newborn intensive and intermediate care units. European Journal of Pediatrics, 1996, 155, 315-322.	1.3	58
36	Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12â€116). Tropical Medicine and International Health, 2008, 13, 1470-1478.	1.0	58

#	Article	IF	CITATIONS
37	Investigation of a Slaughterhouse-Related Outbreak of Q Fever in the French Alps. European Journal of Clinical Microbiology and Infectious Diseases, 2002, 21, 17-21.	1.3	54
38	Factors associated with Efavirenz discontinuation in a large community-based sample of patients. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2004, 16, 558-564.	0.6	50
39	The impact of ledipasvir/sofosbuvir on patientâ€reported outcomes in cirrhotic patients with chronic hepatitis C: the <scp>SIRIUS</scp> study. Liver International, 2016, 36, 42-48.	1.9	50
40	Blood Agar and Mycobacterium tuberculosis : the End of a Dogma. Journal of Clinical Microbiology, 2003, 41, 1710-1711.	1.8	46
41	Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort. Journal of Hepatology, 2017, 67, 23-31.	1.8	45
42	Predictors of Non-adherence to Methadone Maintenance Treatment in Opioiddependent Individuals: Implications for Clinicians. Current Pharmaceutical Design, 2014, 20, 4097-4105.	0.9	44
43	Interventions to address substance use and sexual risk among gay, bisexual and other men who have sex with men who use methamphetamine: A systematic review. Drug and Alcohol Dependence, 2019, 194, 410-429.	1.6	43
44	Clinical, Biologic, and Behavioral Predictors of Early Immunologic and Virologic Response in HIV-Infected Patients Initiating Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 372-376.	0.9	42
45	Innovative communityâ€based educational faceâ€ŧoâ€face intervention to reduce HIV, hepatitis C virus and other bloodâ€borne infectious risks in difficultâ€ŧoâ€reach people who inject drugs: results from the ANRS–AERLI intervention study. Addiction, 2016, 111, 94-106.	1.7	42
46	Immunosuppression and Cancer: A Comparison of Risks in Recipients of Organ Transplants and in HIV-Positive Individuals. Transplantation Proceedings, 2006, 38, 3533-3535.	0.3	41
47	Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 760-765.	0.7	40
48	Acceptability of an "on-demand―pre-exposure HIV prophylaxis trial among men who have sex with men living in France. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 468-477.	0.6	40
49	Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infectious Diseases, The, 2013, 13, 577-586.	4.6	39
50	Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity. Journal of Antimicrobial Chemotherapy, 2015, 70, 1816-1824.	1.3	39
51	â€ <sup>~</sup> Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. Aids, 2001, 15, 1075-1077.	1.0	38
52	Reevaluation of the Risk of Fetal Death and Malformation After Q Fever. Clinical Infectious Diseases, 2014, 59, 256-260.	2.9	37
53	Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCVâ€coinfected patients. Journal of Viral Hepatitis, 2011, 18, e307-14.	1.0	36
54	Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Review of Gastroenterology and Hepatology, 2017, 11, 1-10.	1.4	36

#	Article	IF	CITATIONS
55	Drug injection cessation among HIV-infected injecting drug users. Addictive Behaviors, 2004, 29, 1189-1197.	1.7	35
56	Self-reported side-effects of anti-retroviral treatment among IDUs: A 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). International Journal of Drug Policy, 2007, 18, 288-295.	1.6	35
57	Performance of HIV care decentralization from the patient's perspective: health-related quality of life and perceived quality of services in Cameroon. Health Policy and Planning, 2012, 27, 301-315.	1.0	34
58	Intercenter variability and time of onset: two crucial issues in the analysis of risk factors for nosocomial sepsis. Pediatric Infectious Disease Journal, 2003, 22, 599-609.	1.1	33
59	Longevity of popes and artists between the 13th and the 19th century. International Journal of Epidemiology, 2005, 34, 1435-1436.	0.9	33
60	Antiphospholipid Antibody Syndrome With Valvular Vegetations in Acute Q Fever. Clinical Infectious Diseases, 2016, 62, 537-544.	2.9	33
61	Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduction Journal, 2017, 14, 19.	1.3	33
62	Expanding Access to Non-Medicalized Community-Based Rapid Testing to Men Who Have Sex with Men: An Urgent HIV Prevention Intervention (The ANRS-DRAG Study). PLoS ONE, 2013, 8, e61225.	1.1	32
63	The Role of Adherence in Virological Suppression in Patients Receiving Anti-HBV Analogues. Antiviral Therapy, 2012, 17, 395-400.	0.6	31
64	Adherence to Antiretroviral Treatment in HIV-Positive Patients in the Cameroon Context: Promoting the Use of Medication Reminder Methods. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S40-S43.	0.9	30
65	Correlates of general practitioners' recommendations to patients regarding vaccination for the 2009–2010 pandemic influenza (A/H1N1) in France: Implications for future vaccination campaigns. Vaccine, 2014, 32, 2281-2287.	1.7	29
66	Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: The role of the physician. Drug and Alcohol Dependence, 2011, 116, 228-232.	1.6	28
67	Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, S29-S40.	0.6	28
68	Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDUs. International Journal of STD and AIDS, 2001, 12, 324-328.	0.5	27
69	Prevalence of unsafe sex with one's steady partner either HIV-negative or of unknown HIV status and associated determinants in Cameroon (EVAL ANRS12-116 survey). Sexually Transmitted Infections, 2010, 86, 148-154.	0.8	27
70	European â€~NAFLD Preparedness Index' — Is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports, 2021, 3, 100234.	2.6	27
71	Task Shifting HIV Care in Rural District Hospitals in Cameroon. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 569-576.	0.9	26
72	Treatment and Prophylactic Strategy for Coxiella burnetii Infection of Aneurysms and Vascular Grafts. Medicine (United States), 2016, 95, e2810.	0.4	25

#	Article	IF	CITATIONS
73	Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. Journal of Hepatology, 2017, 67, 1157-1167.	1.8	25
74	Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey). PLoS ONE, 2017, 12, e0171645.	1.1	25
75	Screening, diagnosis and care cascade for viral hepatitis B and C in Yaoundé, Cameroon: a qualitative study of patients and health providers coping with uncertainty and unbearable costs. BMJ Open, 2019, 9, e025415.	0.8	25
76	Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods. Expert Review of Anti-Infective Therapy, 2013, 11, 239-250.	2.0	24
77	Tropheryma whipplei DNA in bronchoalveolar lavage samples: a case control study. Clinical Microbiology and Infection, 2016, 22, 875-879.	2.8	24
78	Knowledge of liver fibrosis stage among adults with <scp>NAFLD</scp> / <scp>NASH</scp> improves adherence to lifestyle changes. Liver International, 2022, 42, 984-994.	1.9	24
79	Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. International Journal of Drug Policy, 2019, 72, 61-68.	1.6	23
80	"Everybody living with a chronic disease is entitled to be cured― Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. International Journal of Drug Policy, 2020, 81, 102766.	1.6	23
81	Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virusâ€coâ€infected patients ( <scp>ANRS CO</scp> 13â€ <scp>HEPAVIH</scp> ). Journal of Viral Hepatitis, 2018, 25, 171-179.	1.0	23
82	Higher risk of unsafe sex and impaired quality of life among patients not receiving antiretroviral therapy in Cameroon: results from the EVAL survey (ANRS 12–116). Aids, 2010, 24, S17-S25.	1.0	22
83	Evaluation of the SIMI system, an experimental computerised network for the surveillance of communicable diseases in Italy. European Journal of Epidemiology, 2000, 16, 941-947.	2.5	21
84	Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). Clinical Infectious Diseases, 2015, 61, 40-48.	2.9	21
85	Comparison of risk factors in HIV-infected men who have sex with men, coinfected or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey). Sexually Transmitted Infections, 2015, 91, 21-23.	0.8	21
86	Increased mortality in HIV/HCV-coinfected compared toÂHCV-monoinfected patients in the DAA era due to non-liver-related death. Journal of Hepatology, 2021, 74, 37-47.	1.8	21
87	Time Patterns of Adherence and Long-Term Virological Response to Non-Nucleoside Reverse Transcriptase Inhibitor Regimens in the Stratall Anrs 12110/Esther Trial in Cameroon. Antiviral Therapy, 2013, 18, 29-37.	0.6	20
88	Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study. PLoS ONE, 2016, 11, e0157062.	1.1	20
89	Mandatory prenatal screening for the human immunodeficiency virus: the experience in south-eastern France of a national policy, 1992-1994. BJOG: an International Journal of Obstetrics and Gynaecology, 1998, 105, 269-274.	1.1	19
90	Physicians' and patients' adherence to antiretroviral prophylaxis after sexual exposure to HIV: results from South-Eastern France. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 537-541.	0.6	19

#	Article	IF	CITATIONS
91	Thrombosis and antiphospholipid antibody syndrome during acute Q fever. Medicine (United States), 2017, 96, e7578.	0.4	19
92	Impaired Anger Control as an Underappreciated Side Effect of Treatments for Chronic HCV Infection in HIV-HCV Coinfected Patients. Journal of Clinical Gastroenterology, 2008, 42, 92-96.	1.1	18
93	Delayed first consultation after diagnosis of HIV infection in Cameroon. Aids, 2009, 23, 1015-1019.	1.0	18
94	No significant effect of cannabis use on the count and percentage of circulating CD4 Tâ€cells in HIVâ€HCV coâ€infected patients (ANRS CO13â€HEPAVIH French cohort). Drug and Alcohol Review, 2017, 36, 227-238.	1.1	18
95	Drug consumption rooms in Catalonia: A comprehensive evaluation of social, health and harm reduction benefits. International Journal of Drug Policy, 2018, 62, 24-29.	1.6	18
96	Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS CO-13 HEPAVIH Cohort). Nutrients, 2018, 10, 705.	1.7	18
97	The Macroeconomic Consequences of Renouncing to Universal Access to Antiretroviral Treatment for HIV in Africa: A Micro-Simulation Model. PLoS ONE, 2012, 7, e34101.	1.1	18
98	Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination. Vaccine, 2011, 29, 8656-8660.	1.7	17
99	The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination. Aids, 2003, 17, 1096-1099.	1.0	17
100	Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus–HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users. Addiction, 2012, 107, 152-159.	1.7	16
101	Low Alcohol Consumption as a Predictor of Higher CD4+ Cell Count in HIV-Treated Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e148-e150.	0.9	16
102	Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRSâ€FANTASIO study). Addiction, 2020, 115, 573-582.	1.7	16
103	Impact of drug maintenance treatment on injection practices among French HIV-infected IDUs. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2000, 12, 461-470.	0.6	15
104	Impact of HAART-related side effects on unsafe sexual behaviours in HIV-infected injecting drug users. Aids, 2004, 18, 1321-1325.	1.0	15
105	Adding HCV Treatment to HIV Treatment in HIV-HCV Coinfected Patients: The Impact on the Different Dimensions of Fatigue and Self-Reported Side Effects. Journal of Pain and Symptom Management, 2007, 34, 413-421.	0.6	15
106	Desire for a child among HIV-infected women receiving antiretroviral therapy in Cameroon: results from the national survey EVAL (ANRS 12-116). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 441-451.	0.6	15
107	Chronic Q Fever Detection in the Netherlands. Clinical Infectious Diseases, 2011, 53, 1170-1171.	2.9	15
108	High Levels of Alcohol Consumption Increase the Risk of Advanced Hepatic Fibrosis in HIV/Hepatitis C Virus-Coinfected Patients: A Sex-Based Analysis Using Transient Elastography at Enrollment in the HEPAVIH ANRS CO13 Cohort. Clinical Infectious Diseases, 2014, 59, 1190-1192.	2.9	15

ſ

#	Article	IF	CITATIONS
109	Statistical fallibility and the longevity of popes: William Farr meets Wilhelm Lexis. International Journal of Epidemiology, 2006, 35, 802-805.	0.9	14
110	Psychosocial correlates of inconsistent condom use among HIV-infected patients enrolled in a structured ART interruptions trial in Côte d'Ivoire: results from the TRIVACAN trial (ANRS 1269). Tropical Medicine and International Health, 2010, 15, 706-712.	1.0	14
111	Non-adherence to aspirin in patients undergoing coronary stenting: Negative impact of comorbid conditions and implications for clinical management. Archives of Cardiovascular Diseases, 2011, 104, 306-312.	0.7	14
112	Empowering HIV testing as a prevention tool: Targeting interventions for high-risk men who have sex with men. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 1039-1045.	0.6	14
113	Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France. Substance Abuse Treatment, Prevention, and Policy, 2017, 12, 46.	1.0	14
114	20-Years of Population-Based Cancer Registration in Hepatitis B and Liver Cancer Prevention in The Gambia, West Africa. PLoS ONE, 2013, 8, e75775.	1.1	14
115	Oral contraception and unprotected sex with occasional partners of women HIV-infected through injection drug use. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2006, 18, 795-800.	0.6	13
116	Individual and Structural Factors Associated With HIV Status Disclosure to Main Partner in Cameroon: ANRS 12-116 EVAL Survey, 2006–2007. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S22-S26.	0.9	13
117	Incidence, Medical and Socio-Behavioural Predictors of Psychiatric Events in An 11-Year Follow-Up of HIV-Infected Patients on Antiretroviral Therapy. Antiviral Therapy, 2012, 17, 1079-1083.	0.6	13
118	Cannabis use is associated with a lower risk of diabetes in chronic hepatitis Câ€infected patients (ANRS) Tj ETQq(	0 0 0 rgBT 1.0	Qyerlock ]
119	Visiting One's Native Country. Journal of the International Association of Providers of AIDS Care, 2013, 12, 407-413.	0.6	12
120	Prevention and care of hepatitis B in the rural region of Fatick in Senegal: a healthcare workers' perspective using a mixed methods approach. BMC Health Services Research, 2019, 19, 627.	0.9	12
121	Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356). BMJ Open, 2019, 9, e030211.	0.8	12
122	HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort). AIDS and Behavior, 2020, 24, 1069-1084.	1.4	12
123	Selfâ€reported alcohol abuse in <scp>HIV</scp> – <scp>HCV</scp> coâ€infected patients: a better predictor of <scp>HIV</scp> virological rebound than physician's perceptions ( <scp>HEPAVIH ARNS CO</scp> 13) Tj ETQq	1 1.0.784	31141 rgBT /0
124	Impact of HCV Treatment and Depressive Symptoms on Adherence to Haart among HIV–HCV-Coinfected Patients: Results from the Anrs-Co13-Hepavih Cohort. Antiviral Therapy, 2014, 19, 171-178.	0.6	11
125	HCV seropositivity in inmates and in the general population: an averaging approach to establish priority prevention interventions. BMJ Open, 2014, 4, e005694.	0.8	11
126	Smoking increases the risk of post-acute COVID-19 syndrome: Results from a French community-based survey. Tobacco Induced Diseases, 2022, 20, 1-10.	0.3	11

#	Article	IF	CITATIONS
127	HIV screening for pregnant women in South Eastern France: evolution 1992–1994–1996. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1998, 76, 5-9.	0.5	10
128	Proximity to HIV is associated with a high rate of HIV testing among men who have sex with men living in Douala, Cameroon. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 1020-1027.	0.6	10
129	Psychometric assessment of health-related quality of life and symptom experience in HIV patients treated with antiretroviral therapy. Quality of Life Research, 2015, 24, 1407-1418.	1.5	10
130	Variations in Cannabis Use Level and Correlates in Opiate-Users on Methadone Maintenance Treatment: A French Prospective Study. Journal of Substance Abuse Treatment, 2015, 58, 100-105.	1.5	10
131	Scaling up combined community-based HIV prevention interventions targeting truck drivers in Morocco: effectiveness on HIV testing and counseling. BMC Infectious Diseases, 2015, 15, 208.	1.3	10
132	A reduced factor structure for the PROQOL–HIV questionnaire provided reliable indicators of health-related quality of life. Journal of Clinical Epidemiology, 2016, 72, 116-125.	2.4	10
133	Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort. Addiction, 2017, 112, 1669-1679.	1.7	10
134	Decrease in self-reported offences and incarceration rates during methadone treatment: A comparison between patients switching from buprenorphine to methadone and maintenance treatment incident users (ANRS-Methaville trial). International Journal of Drug Policy, 2017, 39, 86-91.	1.6	10
135	Self-Reported Bothersome Symptoms Across Different Socioepidemiological Groups of People Living With HIV Attending French Hospitals: Results From the ANRS-VESPA2 Survey. Journal of Pain and Symptom Management, 2017, 54, 110-119.	0.6	10
136	Efficacy, safety and patientâ€reported outcomes of ledipasvir/sofosbuvir in <scp>NS</scp> 3/4A protease inhibitorâ€experienced individuals with hepatitis C virus genotype 1 and <scp>HIV</scp> coinfection with and without cirrhosis ( <scp>ANRS HC</scp> 31 <scp>SOFTRIH</scp> study). HIV Medicine, 2018, 19, 227-237.	1.0	10
137	Factors associated with perceived loss of libido in people who inject opioids: Results from a community-based survey in France. Drug and Alcohol Dependence, 2018, 190, 121-127.	1.6	10
138	Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. World Journal of Hepatology, 2018, 10, 856-866.	0.8	10
139	Hospitalization for depressive syndrome in a cohort of HIV-infected patients contaminated through injecting drug use: MANIF 2000 cohort, France, 1995-1999. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2003, 15, 729-734.	0.6	9
140	Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV–HCV co-infected patients: ANRS Co13 Hepavih, France, 2006–2008. Journal of Viral Hepatitis, 2009, 17, 650-60.	1.0	9
141	Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy. BMJ Open, 2012, 2, e001155.	0.8	9
142	Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Services Research, 2012, 12, 59.	0.9	9
143	Factors associated with guidelineâ€based hepatitis <scp>C</scp> virus ( <scp>HCV</scp> ) treatment initiation in <scp>HIV</scp> / <scp>HCV</scp> â€coinfected patients: role of comorbidities and physicians' perceptions. HIV Medicine, 2013, 14, 430-436.	1.0	9
144	Factors Associated with HIV Status Disclosure in HIV-Infected Sub-Saharan Migrants Living in France and Successfully Treated with Antiretroviral Therapy: Results from the ANRS-VIHVO Study. Journal of Immigrant and Minority Health, 2017, 19, 843-850.	0.8	9

#	Article	IF	CITATIONS
145	The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients. Journal of Hepatology, 2018, 68, 845-847.	1.8	9
146	Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol. BMJ Open, 2019, 9, e023683.	0.8	9
147	Adherence as a Predictor of Sexual Behaviors in People Living with HIV/AIDS during the First Year of Antiretroviral Therapy in Rural Cameroon: Data from Stratall ANRS 12110/ESTHER Trial. PLoS ONE, 2012, 7, e36118.	1.1	9
148	Severe liver disease related to chronic hepatitis C virus infection in treatment-naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014. Eurosurveillance, 2017, 22, .	3.9	9
149	Serum Clara cell protein (CC16) in healthy young smokers. Biomarkers, 2000, 5, 158-164.	0.9	8
150	Depressive Symptoms and Exposure to Efavirenz in West African HIV-Infected Adults. HIV Clinical Trials, 2008, 9, 445-447.	2.0	8
151	Changes in supervised drug-injecting practices following a community-based educational intervention: A longitudinal analysis. Drug and Alcohol Dependence, 2018, 192, 1-7.	1.6	8
152	Elevated Fatty Liver Index as a Risk Factor for Allâ€Cause Mortality in Human Immunodeficiency Virus–Hepatitis C Virus–Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). Hepatology, 2020, 71, 1182-1197.	3.6	8
153	HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study). AIDS and Behavior, 2021, 25, 4141-4153.	1.4	8
154	Peer presence and familiarity as key factors to reduce cocaine intake in both rats and humans: an effect mediated by the subthalamic nucleus. Psychopharmacology, 2022, 239, 1097-1113.	1.5	8
155	Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). Clinical Nutrition, 2022, 41, 610-619.	2.3	8
156	De jure decriminalisation of cannabis use matters: some recent trends from France. International Journal of Drug Policy, 2013, 24, 634-635.	1.6	7
157	Short article: Fatigue in the long term after HCV treatment in HIV–HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). European Journal of Gastroenterology and Hepatology. 2016. 28. 1003-1007.	0.8	7
158	Importance of the patientâ€physician interaction in assessing acceptability of HIV cure trials. HIV Medicine, 2018, 19, e56-e57.	1.0	7
159	Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRSÂCO13 HEPAVIH). Journal of Hepatology, 2020, 72, 588-591.	1.8	7
160	Coffee Intake and Neurocognitive Performance in HIV/HCV Coinfected Patients (ANRS CO13 HEPAVIH). Nutrients, 2020, 12, 2532.	1.7	7
161	Pain in methadone patients: Time to address undertreatment and suicide risk (ANRS-Methaville trial). PLoS ONE, 2017, 12, e0176288.	1.1	7
162	PASSI d'Argento (Silver Steps): the main features of the new nationwide surveillance system for the ageing Italian population, Italy 2013-2014. Annali Dell'Istituto Superiore Di Sanita, 2016, 52, 536-542.	0.2	7

#	Article	IF	CITATIONS
163	Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey). Hepatology Communications, 2022, 6, 1005-1015.	2.0	7
164	Perceived stigma, substance use and self-medication in night-shift healthcare workers: a qualitative study. BMC Health Services Research, 2022, 22, .	0.9	7
165	Relationship between HIV-1 viral load and continued drug use in untreated infected injection drug users. Addiction Biology, 1999, 4, 197-202.	1.4	6
166	Determinants of benzodiazepine use in a representative population of HIV-infected individuals: the role of HIV status disclosure (ANRS-EN12-VESPA study). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 1163-1170.	0.6	6
167	Choice of therapeutic strategies in the context of HIV infection: key role of patient-reported outcomes. Expert Review of Anti-Infective Therapy, 2012, 10, 403-406.	2.0	6
168	Prediction of HIV Drug Resistance Based on Virologic, Immunologic, Clinical, and/or Adherence Criteria in the Stratall ANRS 12110/ESTHER Trial in Cameroon. Clinical Infectious Diseases, 2013, 57, 604-607.	2.9	6
169	Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon – Data from the STRATALL ANRS 12110/ESTHER trial. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 347-355.	0.6	6
170	Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients. Aids, 2014, 28, 1155-1160.	1.0	6
171	Life after hepatitis C cure in HIVâ€infected people who inject drugs and men who have sex with men treated with directâ€acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH). Journal of Viral Hepatitis, 2020, 27, 1462-1472.	1.0	6
172	Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). Expert Review of Anti-Infective Therapy, 2021, 19, 1147-1156.	2.0	6
173	Twelve-year mortality in HIV-infected patients receiving antiretroviral therapy (ART): the role of social vulnerability. The ANRS CO8 APROCO-COPILOTE cohort. Antiviral Therapy, 2015, 20, 763-772.	0.6	6
174	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). Cannabis and Cannabinoid Research, 2022, 7, 677-689.	1.5	6
175	EXPANDED ACCESS TO SEPs AND OTHER HARM REDUCTION MEASURES IN FRANCE. Addiction, 2009, 104, 1447-1448.	1.7	5
176	Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. Expert Review of Gastroenterology and Hepatology, 2014, 8, 351-358.	1.4	5
177	Psychiatric and substance use disorders in <scp>HIV</scp> /hepatitis C virus ( <scp>HCV</scp> )â€coinfected patients: does <scp>HCV</scp> clearance matter? [Agence Nationale de Recherche sur le <scp>SIDA</scp> et les Hépatites Virales ( <scp>ANRS</scp> ) <scp>HEPAVIH CO</scp> 13 cohort]. HIV Medicine. 2016. 17. 758-765.	1.0	5
178	Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection. Aids, 2020, 34, 953-954.	1.0	5
179	Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). Liver International, 2022, 42, 38-49.	1.9	5
180	Use of psychoactive substances by night-shift hospital healthcare workers during the first wave of the COVID-19 pandemic: a cross-sectional study based in Parisian public hospitals (ALADDIN). BMJ Open, 2022, 12, e055699.	0.8	5

#	Article	IF	CITATIONS
181	Health-care-associated bloodstream infections in France. Lancet Infectious Diseases, The, 2013, 13, 656.	4.6	4
182	Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study). Expert Review of Gastroenterology and Hepatology, 2015, 9, 701-713.	1.4	4
183	Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. HIV Clinical Trials, 2016, 17, 63-71.	2.0	4
184	Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). Patient, 2017, 10, 605-614.	1.1	4
185	France removes hepatitis C treatment prescriber restrictions—But what is the impact of the delay for key populations?. Liver International, 2019, 39, 2418-2419.	1.9	4
186	Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit. European Journal of Gastroenterology and Hepatology, 2020, 32, 1212-1221.	0.8	4
187	Application of Functional Data Analysis to Identify Patterns of Malaria Incidence, to Guide Targeted Control Strategies. International Journal of Environmental Research and Public Health, 2020, 17, 4168.	1.2	4
188	Correlates of Self-Reported Cotton Fever Experience among People Who Inject Opioids. Substance Use and Misuse, 2020, 55, 1021-1027.	0.7	4
189	Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS) Tj ETQq1	0,784314 1.3	rgBT /Overl
190	Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER). Harm Reduction Journal, 2022, 19, 2.	1.3	4
191	Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France. PLoS ONE, 2022, 17, e0261069.	1.1	4
192	Stigma and care avoidance in people with unhealthy alcohol use: A call for research and action. Journal of Hepatology, 2022, 77, 1221-1222.	1.8	4
193	Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active Antiretroviral Therapy. Clinical Therapeutics, 1999, 21, 1313-1320.	1.1	3
194	Risk factors for adherence failure in HIV-infected sub-Saharan migrants living in France and travelling back to their native country. International Journal of STD and AIDS, 2014, 25, 389-390.	0.5	3
195	Increasing access to opioid maintenance treatment: The role of primary care in France. International Journal of Drug Policy, 2015, 26, 434-435.	1.6	3
196	HIV infection among persons who inject drugs. Aids, 2016, 30, 1858-1859.	1.0	3
197	The need for patient-tailored dosing of baclofen in future clinical trialsâ~†. European Neuropsychopharmacology, 2018, 28, 656-657.	0.3	3
198	Impact of an educational intervention on risks associated with drug injection, and on psychosocial factors (PSF) involved in initiating and maintaining new health behaviors over time. Addictive Behaviors, 2018, 87, 222-230.	1.7	3

#	Article	IF	CITATIONS
199	Profile, risk practices and needs of people who inject morphine sulfate: Results from the ANRS-AERLI study. International Journal of Drug Policy, 2018, 59, 3-9.	1.6	3
200	Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. PLoS ONE, 2018, 13, e0199874.	1.1	3
201	Cannabinoids and reduced risk of hepatic steatosis in HIV-HCV co-infection: paving the way for future clinical research. Expert Review of Anti-Infective Therapy, 2018, 16, 377-380.	2.0	3
202	Factors Associated with Virological Rebound in HIV-Positive Sub-Saharan Migrants Living in France After Traveling Back to Their Native Country: ANRS-VIHVO 2006–2009 Study. Journal of Immigrant and Minority Health, 2019, 21, 1342-1348.	0.8	3
203	Effectiveness of directâ€acting antivirals for chronic hepatitis C treatment in migrant and nonâ€migrant populations in France. Liver International, 2021, 41, 2328-2340.	1.9	3
204	Posttraumatic Stress Disorder as a Significant Correlate of Voluntary Antiretroviral Treatment Interruption in Adult HIV-Infected Patients Followed up in French Hospitals. Journal of Clinical Psychiatry, 2018, 79, .	1.1	3
205	Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort). Liver International, 2022, 42, 249-252.	1.9	3
206	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. JHEP Reports, 2022, 4, 100481.	2.6	3
207	The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 232-239.	0.9	2
208	Decentralization of access to antiretroviral therapy in Cameroon: correlates of HIV physicians' knowledge in HIV care. Antiviral Therapy, 2011, 16, 423-428.	0.6	2
209	Impaired patientâ€reported outcomes persist in <scp>HIV</scp> â€ <scp>HCV</scp> coâ€infected patients and in cirrhotic patients despite <scp>HCV</scp> clearance. Journal of Viral Hepatitis, 2018, 25, 314-315.	1.0	2
210	No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH) Tj ETQq0 0	0_rgBT /O	verlock 10 T
211	Direct, indirect and total effect of HIV coinfection on the risk of nonâ€liverâ€related cancer in hepatitis C virusâ€infected patients treated by directâ€acting antivirals: a mediation analysis. HIV Medicine, 2021, 22, 924-935.	1.0	2
212	Postâ€HCV cure selfâ€reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH). Journal of Viral Hepatitis, 2021, 28, 1665-1667.	1.0	2
213	Social vulnerability of patients co-infected with hepatitis B and hepatitis delta viruses: Data from the ANRS CO22 HEPATHER cohort. Journal of Clinical Virology, 2021, 144, 104987.	1.6	2
214	De la recherche communautaire à la transformation socialeÂ: l'exemple du projet ANRS-AERLI surÂl'accompagnement et l'éducation aux risques liés à l'injection. Psychotropes (discontinued), Vol. 23, 57-72.	2007,	2
215	Reduced delays in time to first HIV consultation after diagnosis in France in the antiretroviral therapy era: the possible role of a free care system. HIV Medicine, 2011, 12, 383-384.	1.0	1
216	Non Adherence to Thienopyridine after Coronary Stenting. American Journal of Cardiology, 2011, 107, 1866-1867.	0.7	1

#	Article	IF	CITATIONS
217	Reconceptualizing Research on HIV Treatment Outcomes Among Criminalized Groups. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 329-330.	0.9	1
218	Cocoa and Chocolate: Chemistry, Biochemistry, and Beneficial Brain Effects. , 2013, , 389-406.		1
219	Time to combine intervention with prevention in countries where <scp>HIV</scp> is also driven by hazardous drinking. Addiction, 2013, 108, 221-222.	1.7	1
220	No condoms for prisoners: accumulating risks of HIV, STI but also hepatitis transmission. Sexually Transmitted Infections, 2013, 89, 310-310.	0.8	1
221	Securing opioid substitution treatment access and quality for people who inject drugs. Aids, 2015, 29, 975-976.	1.0	1
222	Role of communityâ€based research in advocating <scp>HCV</scp> prevention and care. Journal of the International AIDS Society, 2017, 20, e25005.	1.2	1
223	Letter to the Editor: Patientâ€Reported Outcomes for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: Rationale for Expanded Use. Hepatology, 2019, 70, 443-444.	3.6	1
224	Wine Consumption and Lower Risk of Advanced Liver Fibrosis: A True Effect or Unmeasured Confounding? A Longitudinal Analysis (ANRS CO13 HEPAVIH Cohort). American Journal of Gastroenterology, 2018, 113, 1729-1732.	0.2	1
225	Methadone in primary care in France: Using evidence for action against hepatitis C. International Journal of Drug Policy, 2019, 71, 91-92.	1.6	1
226	Risk of invasive cervical cancer among women with, or at risk for, HIV infection. International Journal of Cancer, 1999, 82, 334-337.	2.3	1
227	HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH) Tj ET	Qq1_1 0.7	84314 rgB⊺
228	Impact of the <scp>COVID</scp> â€19 crisis on healthcare workers: The need to address quality of working life issues. Respirology, 2022, 27, 469-471.	1.3	1
229	Quality of life assessment in HIV clinical research in resource-limited settings: better late than never. Tropical Medicine and International Health, 2010, 15, no-no.	1.0	0
230	Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT). Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 56-65.	0.7	0
231	Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort). Digestive Diseases and Sciences, 2017, 62, 2943-2944.	1.1	0
232	Reply to: "Coffee consumption and decreased all-cause mortality – What is the true estimate of effect?― Journal of Hepatology, 2018, 68, 1106.	1.8	0
233	Une analyse de Twitter pour mieux comprendre les acteurs de la communication des nouvelles drogues et leurs discussions. , 2018, , .		0
234	Alcohol Use Patterns and Liver Outcomes: Is There Really a Difference Between Drinking Beer and Drinking Wine?. Clinical Gastroenterology and Hepatology, 2020, 18, 1650-1651.	2.4	0

#	Article	IF	CITATIONS
235	Quality of Life in HIV Positive Injecting Drug Users. , 2010, , 3705-3725.		Ο